Global disparities in hepatocellular carcinoma care: insights from the ESGAR Global Abdominal Imaging Forum

OBJECTIVES: To analyze the intercontinental differences and inequities in the management of hepatocellular carcinoma (HCC), including surveillance, diagnosis, and treatment, through the survey responses from the participants of the Global Abdominal Imaging Forum on HCC, organized by the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). MATERIALS AND METHODS: An online anonymous survey was distributed to the attendees of the Global Abdominal Imaging Forum on HCC. The survey consisted of 14 multiple-choice questions, covering demographic, epidemiological and occupational data, and information on the management of HCC. Global differences and differences between European and non-European countries were analyzed. RESULTS: Of 1963 attendees from 110 countries, 408 (20.8%) from 67 countries responded to the survey. Multidisciplinary HCC meetings were reported with the highest frequency in North America (83.3%) and the lowest in Africa (41.2%). The most commonly reported tools for HCC surveillance were ultrasound (86.8%) and serum alpha-fetoprotein (79.4%). Global inequities were reported for contrast-enhanced ultrasound (p < 0.001, lowest access in South America, Africa, and Asia), MRI (p < 0.001, lowest access in Africa) and PET/CT (p < 0.001, lowest access in Africa). LI-RADS was the most common algorithm used for HCC diagnosis (83.6%), with the highest use reported in North America (94.4%). Heterogeneity in treatment availability was observed, with respondents from Africa reporting limited availability of surgery (41.2%), locoregional treatments (23.5%), liver transplantation (0%), and immunotherapy (17.6%). CONCLUSION: Although the surveillance strategy for HCC is similar at a global level, disparities exist in access to CEUS, MRI, PET/CT, and treatments for HCC. KEY POINTS: Question What are the global disparities in hepatocellular carcinoma surveillance, diagnosis, and treatment reported by doctors working in different continents? Findings The survey from the Global Abdominal Imaging Forum on HCC revealed significant global variability with disparities regarding access to advanced imaging modalities and treatments, particularly affecting Africa. Clinical relevance Global efforts should focus on improving access to advanced imaging techniques (including MRI and PET/CT) and treatments (including transplantation and immunotherapy). Guidelines for the management of HCC should consider the existing regional disparities in healthcare infrastructure and resource availability to ensure more equitable HCC care worldwide.

Authors

Institutions

Publication Details

Journal
European Radiology
Published
2026-06-09
DOI
https://doi.org/10.1007/s00330-026-12567-8
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global disparities in hepatocellular carcinoma care: insights from the ESGAR Global Abdominal Imaging Forum

Roberto Cannella, Marc Zins, Federica Vernuccio, D. Tolan et al.
European Radiology
Hepatocellular Carcinoma Treatment and Prognosis
article

Global disparities in hepatocellular carcinoma care: insights from the ESGAR Global Abdominal Imaging Forum

Roberto Cannella, Marc Zins, Federica Vernuccio, D. Tolan, Giuseppe Brancatelli, Cäcilia S. Reiner, Katja N. De Paepe, Valérie Vilgrain
article en

Abstract

OBJECTIVES: To analyze the intercontinental differences and inequities in the management of hepatocellular carcinoma (HCC), including surveillance, diagnosis, and treatment, through the survey responses from the participants of the Global Abdominal Imaging Forum on HCC, organized by the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). MATERIALS AND METHODS: An online anonymous survey was distributed to the attendees of the Global Abdominal Imaging Forum on HCC. The survey consisted of 14 multiple-choice questions, covering demographic, epidemiological and occupational data, and information on the management of HCC. Global differences and differences between European and non-European countries were analyzed. RESULTS: Of 1963 attendees from 110 countries, 408 (20.8%) from 67 countries responded to the survey. Multidisciplinary HCC meetings were reported with the highest frequency in North America (83.3%) and the lowest in Africa (41.2%). The most commonly reported tools for HCC surveillance were ultrasound (86.8%) and serum alpha-fetoprotein (79.4%). Global inequities were reported for contrast-enhanced ultrasound (p < 0.001, lowest access in South America, Africa, and Asia), MRI (p < 0.001, lowest access in Africa) and PET/CT (p < 0.001, lowest access in Africa). LI-RADS was the most common algorithm used for HCC diagnosis (83.6%), with the highest use reported in North America (94.4%). Heterogeneity in treatment availability was observed, with respondents from Africa reporting limited availability of surgery (41.2%), locoregional treatments (23.5%), liver transplantation (0%), and immunotherapy (17.6%). CONCLUSION: Although the surveillance strategy for HCC is similar at a global level, disparities exist in access to CEUS, MRI, PET/CT, and treatments for HCC. KEY POINTS: Question What are the global disparities in hepatocellular carcinoma surveillance, diagnosis, and treatment reported by doctors working in different continents? Findings The survey from the Global Abdominal Imaging Forum on HCC revealed significant global variability with disparities regarding access to advanced imaging modalities and treatments, particularly affecting Africa. Clinical relevance Global efforts should focus on improving access to advanced imaging techniques (including MRI and PET/CT) and treatments (including transplantation and immunotherapy). Guidelines for the management of HCC should consider the existing regional disparities in healthcare infrastructure and resource availability to ensure more equitable HCC care worldwide.

European Radiology
Beth Israel Deaconess Medical Center (US), Harvard University (US), University of Zurich (CH), Université Paris Cité (FR), Leeds Teaching Hospitals NHS Trust (GB), Hôpital Beaujon (FR), Assistance Publique – Hôpitaux de Paris (FR), Klinik Hirslanden (CH), Hôpital Marie Lannelongue (FR), Centre de Recherche sur l'Inflammation (FR), University of Palermo (IT), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 7%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.